Head-to-head evidence
Recaticimab vs SYH2053
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Atherosclerotic Cardiovascular Disease
Shared mechanism: PCSK9 · full Atherosclerotic Cardiovascular Disease pipeline
Recaticimab
Developed by Jiangsu Hengrui Pharmaceuticals
NCT04849000 · Phase 3 · completed
This was a randomized, quadruple-blind, placebo-controlled trial with 709 participants, using percentage change in LDL cholesterol as the primary measure. The sponsor reports statistically significant LDL reductions of 45 to 53 percentage points versus placebo across all three dosing regimens.
SYH2053
Developed by CSPC Pharmaceutical Group
NCT07421232 · Phase 2 · completed
The trial was randomized and participant-blinded, with placebo and inclisiran comparator groups, and enrolled 156 participants. Its primary endpoint was the clinically accepted LDL-C measure, but the outcome comparison cannot yet be assessed because results are not available.
Next expected readout: December 2027 · NCT07421284 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Recaticimab's landscape · SYH2053's landscape